Armistice Capital reports 9.85% stake in Treace Medical

Treace Medical Concepts, Inc. reported a Schedule 13G/A amendment showing Armistice Capital, LLC and Steven Boyd beneficially own 6,364,000 shares of common stock, representing 9.85% of the class as reported.

Rhea-AI Filing Summary

Treace Medical Concepts, Inc. reported a Schedule 13G/A amendment showing Armistice Capital, LLC and Steven Boyd beneficially own 6,364,000 shares of common stock, representing 9.85% of the class as reported. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over those shares.

The statement identifies the Reporting Persons, gives principal addresses, and includes a joint filing statement and signatures dated May 15, 2026. The filing explains the Master Fund holds the shares and disclaims beneficial ownership to the extent of its inability to vote or dispose of the securities due to the Investment Management Agreement.

Insights

Institutional Ownership Analyst

Armistice holds a near‑10% stake reported via amendment.

The filing documents a 6,364,000 share position, labeled as 9.85% of the class and attributed to Armistice Capital through its management of the Master Fund. The filing clarifies voting and dispositive power are exercised by Armistice Capital under an Investment Management Agreement.

This disclosure updates public ownership records and may affect calculations of major‑holder thresholds; timing and further disposition are not addressed in the excerpt.

Corporate Governance Advisor

Filing clarifies attribution and joint filing responsibilities.

The document includes a joint filing statement under Rule 13d‑1(k) and signatures, indicating coordinated reporting between Armistice Capital and Steven Boyd. It also states the Master Fund retains legal title while disclaiming direct voting/dispositive authority.

Stakeholders can use this filing to confirm who reports control rights; any changes in voting or sales would require separate disclosures.

Key Figures

Beneficial ownership: 6,364,000 shares Percent of class: 9.85% Shared voting power: 6,364,000 shares +2 more

5 metrics

Beneficial ownership 6,364,000 shares Amount beneficially owned reported in Item 4(a)

Percent of class 9.85% Percent of class reported in Item 4(b)

Shared voting power 6,364,000 shares Item 4(c)(ii) shared power to vote

Shared dispositive power 6,364,000 shares Item 4(c)(iv) shared power to dispose

Signature date May 15, 2026 Filing signature date

Key Terms

beneficially own, Investment Management Agreement, Rule 13d-1(k)

3 terms

beneficially own regulatory

"Armistice Capital is the investment manager ... and thus may be deemed to beneficially own"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Investment Management Agreement regulatory

"as a result of its Investment Management Agreement with Armistice Capital"

An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.

Rule 13d-1(k) regulatory

"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Armistice Capital report in TMCI?

Armistice Capital reports beneficial ownership of 6,364,000 shares, representing 9.85% of Treace Medical Concepts' common stock, as stated in the Schedule 13G/A amendment.

Who is the reporting person for the 13G/A filed for TMCI?

The filing is by Armistice Capital, LLC and Steven Boyd, with addresses at 510 Madison Avenue, New York, and signed May 15, 2026, per the submitted amendment.

Does the Master Fund directly control the reported TMCI shares?

The Master Fund holds the shares but the filing states Armistice Capital, as investment manager, exercises the voting and dispositive power under an Investment Management Agreement and the Master Fund disclaims direct beneficial ownership to the extent described.

What voting/dispositive powers are reported by Armistice Capital for TMCI?

The Schedule 13G/A shows 0 sole and 6,364,000 shared voting power and 0 sole and 6,364,000 shared dispositive power over the reported shares.

When was the Schedule 13G/A amendment signed for TMCI?

The joint amendment is signed by Steven Boyd on May 15, 2026, as shown in the signature block of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 11:19 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Treace Medical Concepts, Inc.

(Name of Issuer)

Common stock, $0.001 par value

(Title of Class of Securities)

89455T109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 89455T109

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,364,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,364,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,364,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.85 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 89455T109

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,364,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,364,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,364,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.85 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Treace Medical Concepts, Inc.
(b)	Address of issuer's principal executive offices: 100 PALMETTO PARK PLACE, PONTE VEDRA, FL, 32081
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common stock, $0.001 par value
(e)	CUSIP No.: 89455T109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,364,000
(b)	Percent of class: 9.85%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 6,364,000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 6,364,000 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	05/15/2026

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	05/15/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd